Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women
- 749 Downloads
Adherence is now one of the major issues in the management of osteoporosis and several papers have suggested that vertebral fractures might be increased in patients who do not follow appropriately their prescriptions. This paper relates the strong relationship existing between adherence to anti-osteoporosis treatment and the risk of subsequent hip fracture.
A study was performed to investigate adherence to bisphosphonate (BP) therapy and the impact of adherence on the risk of hip fracture (Fx).
An exhaustive search of the Belgian national social security database was conducted. Patients enrolled in the study were postmenopausal women, naïve to BP, who received a first prescription of alendronate. Compliance at 12 months was quantified using the medication possession ratio (MPR). Persistence was calculated as the number of days from the initial prescription to a gap of more than 5 weeks after completion of the previous refill. A logistic regression model was used to estimate the impact of compliance on the risk of hip fracture. The impact of persistence on hip fracture risk was analysed using the Cox proportional hazards model.
The mean MPR at 12 months was significantly higher among patients receiving weekly (n = 15.021) compared to daily alendronate (n = 14,136) (daily = 58.6%; weekly = 70.5%; p < 0.001). At 12 months, the rate of persistence was 39.45%. For each decrease of the MPR by 1%, the risk of hip Fx increased by 0.4% (OR: 0.996; CI95%:0.994–0.998; p < 0.001). The relative risk reduction for hip Fx was 60% (HR: 0.404;CI95%:0.357–0.457; p < 0.0001) for persistent compared to non-persistent patients.
These results confirm that adherence to current therapeutic regimens remains suboptimal.
KeywordsAdherence Bisphosphonates Hip fracture Osteoporosis
- 1.Hodgson SF, Watts NB, Bilezikian JP et al (2004) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544–564Google Scholar
- 3.Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352CrossRefPubMedGoogle Scholar
- 11.Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax international trial study group. Osteoporos Int 9:461–468CrossRefPubMedGoogle Scholar
- 12.Eastell R, Garnero P, Vrijens B et al (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:P297Google Scholar
- 13.Finigan J, Bainbridge PR, Eastell R (2001) Adherence to osteoporosis therapies. Osteoporos Int 12:S48–S49 P110Google Scholar
- 15.Sebaldt RJ, Shane LG, Pham B et al (2004) Longer term effectiveness outcomes of noncompliance and nonpersistence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int 15(Suppl 1):S107P391SAGoogle Scholar